AMAG Pharmaceuticals, Inc. is an American
pharmaceutical company
The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...
developing products that treat
iron deficiency anemia
Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number of red blood cells or the amount of hemoglobin in the blood. When onset is slow, symptoms are often vague such as feeling tired, weak, s ...
(IDA) in adult patients. The company was a publicly traded company listed on
NASDAQ under the symbol "AMAG" until November 2020 when it was acquired by Covis Pharma.
In 2016, the company became a member of the
Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced ), formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 195 ...
(PhRMA).
Operations
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.
AMAG's main product,
Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013.
In August 2013, the company received a new
U.S. patent for Ferumoxytol, expiring in 2020.
In June 2015, the company acquired Cord Blood Registry for $700 million.
In 2014, AMAG acquired Lumara Health, formerly
KV Pharmaceutical Company.
In 2015, the company's revenue reached $418 million. AMAG had 552 employees.
In December 2018, AMAG announced it would acquire Perosphere Pharmaceuticals Inc.
In October 2020, Covis Group agreed to acquire AMAG for $498 million.
Drug approvals and distribution
The company's research and tests focus on
iron deficiency anemia
Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number of red blood cells or the amount of hemoglobin in the blood. When onset is slow, symptoms are often vague such as feeling tired, weak, s ...
and related intravenous drugs.
In June 2009, the company's main product
Ferumoxytol, an oral medication used on adult patients with chronic kidney disease, was approved by US
Food and Drug Administration
The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...
.
In December 2011,
Health Canada approved Ferumoxytol, under the brand name Feraheme, for use in treating both dialysis and non-dialysis dependent
chronic kidney disease patients, as well as for treatment of adult patients with
iron deficiency anemia
Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number of red blood cells or the amount of hemoglobin in the blood. When onset is slow, symptoms are often vague such as feeling tired, weak, s ...
.
From 2010 to 2014, AMAG had a distribution agreement with
which granted them exclusivity to the Canadian and European Union markets, where the drug is sold under the brand names
Feraheme and
Rienso, respectively.
References
External links
*
{{authority control
Companies formerly listed on the Nasdaq
Pharmaceutical companies established in 1981
Companies based in Lexington, Massachusetts
2020 mergers and acquisitions
Pharmaceutical companies of the United States
Health care companies based in Massachusetts
1981 establishments in Massachusetts